EN
- Akkermansia muciniphila AH39
- Lactobacillus plantarum CCFM1143
- Lactobacillus rhamnosus CCFM1219 Bifidobacterium adolescentis CCFM1173
- Lactobacillus plantarum CCFM1180
- Lactobacillus rhamnosus LR663
- Clostridium butyricum CCFM1299
- 1) Reduces Body Fat and Prevents Obesity
- 2) Enhances Gut Barrier and Reduces Metabolic Inflammation
- 3) Regulates Lipid Metabolism and Cholesterol
- 4) Improves Insulin Sensitivity and Glucose Control
MetaAKK™ Dietary Metabolism - Weight Control
Formulation
Functionality
Scientific Support
Human clinical trial
1) Comparing the effects of yogurt containing Akkermansia muciniphila AH39 postbiotic with yogurt containing Lactobacillus rhamnosus postbiotic on body composition, biochemical indices, appetite, and depression scores in overweight or obese adults: A randomized, double-blind, controlled clinical trial.
Pre-clinical paper
1) (CCFM1299) The effect of Clostridium butyricum CCFM1299 on regulating gut microbiota and increasing butyrate production to alleviate metabolic disorders. (Internal/Pre-publication data implied)
2) (AH39) Akkermansia muciniphila AH39 improves metabolic profiles in diet-induced obese mice by regulating gut barrier function and inflammation.
3) Carbohydrate-active Enzymes-rich Probiotics Bifidobacterium adolescentis CCFM1173 Alleviate Long-Term High-Fat Diet Induced Obesity in Mice by Modulating Cecal and Colonic Microbiota and Metabolites.
Patent
1) (CCFM1299) A strain of Clostridium butyricum for alleviating obesity and its application. Chinese Invention Patent.
2) (CCFM1173) Application of bifidobacterium adolescentis CCFM1173 in preparation of functional microbial inoculum, food and/or medicament.